Intellectual Property Protection
The Congress in Uruguay is considering a draft bill presented by the Executive, dated December 30, 1997, that is deficient and contrary to the interests of the research-based pharmaceutical industry. In the most general terms:
- Compulsory licensing is very broadly established;
- Data exclusivity is omitted;
- Exclusive marketing rights are not considered;
- Pipeline patent protection is not considered;
- Parallel importation is allowed.
The contents of the draft bill have not been fully endorsed by the research-based industry. Accordingly, any statements to the contrary from the Government of Uruguay and local groups should be understood in the proper light, as reflecting a "consensus" on the need for draft legislation, rather than agreement on its substance.
Potential Export/Foreign Sales
The removal of current barriers would mean an increase in sales and exports in the range of US$ 50 million to US$100 million for PhRMA members.
For all the aforementioned reasons, PhRMA believes that Uruguay should be listed as a Watch Country under Special 301 in 1999.